^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CCR7 positive

i
Other names: CCR7, BLR2, CD197, CDw197, CMKBR7, EBI1, Chemokine (C-C motif) receptor 7
Entrez ID:
Related biomarkers:
3ms
Lymphatic endothelial-like cells promote glioblastoma stem cell growth through cytokine-driven cholesterol metabolism. (PubMed, Nat Cancer)
Expression of the CCL21-CCR7 axis correlated with KAT5 expression and HMGCS1 acetylation in glioblastoma specimens, informing patient outcome. Collectively, glioblastomas contain previously unrecognized LECs that promote the molecular crosstalk between endothelial and tumor cells, offering potentially alternative therapeutic strategies.
Journal
|
CCR7 (Chemokine (C-C motif) receptor 7) • CCL21 (C-C Motif Chemokine Ligand 21) • HMGCS1 (3-Hydroxy-3-Methylglutaryl-CoA Synthase 1)
|
CCR7 positive
4ms
Nanoporous Substrates to Advance CAR-T Cell Production for Advanced Cell Therapies (ASH 2023)
Our preliminary data strongly supports the potential of our innovative immUni technology to enhance CAR-T cell production. Comparative studies against Dynabeads TM demonstrate that our technology outperforms current methods with abbreviated T cell activation time, enhanced gene transfer, and robust cytokine production. The accelerated expansion of CAR-T cells, coupled with the retention of a memory-related phenotype, holds great promise for effective tumor eradication, currently under preclinical validation.
CAR T-Cell Therapy • IO biomarker • Metastases
|
CD8 (cluster of differentiation 8) • CD69 (CD69 Molecule) • CCR7 (Chemokine (C-C motif) receptor 7) • FAS (Fas cell surface death receptor) • IL15 (Interleukin 15) • IL7 (Interleukin 7)
|
CCR7 positive
8ms
Health prevention intervention for chronic tissue fibrosis: Based on the specific expression of CCL19/21 + mast cell. (PubMed, Prev Med)
In disease tissue fibrosis, mast cell activation may increase the expression of chemokines, especially CCL19, in the tissue, thereby inducing a large number of CCR7-positive fibroblasts to migrate to specific tissues. This study lays a foundation for the mechanism of tissue fibrosis and provides evidence for the mechanism by which mast cells induce fibroblast migration.Through the experimental results of this paper, we can combine the induction factors of chronic tissue fibrosis and put forward targeted health prevention strategies.
Journal
|
CCL19 (C-C Motif Chemokine Ligand 19) • CCR7 (Chemokine (C-C motif) receptor 7) • CD14 (CD14 Molecule) • CCL21 (C-C Motif Chemokine Ligand 21)
|
CCR7 positive
over1year
EXPRESSION OF CHEMOKINE (C-C MOTIF) RECEPTOR 7 IN PROSTATE CANCER TISSUE OF YOUNG PATIENTS AND IN METASTATIC CANCER CELLS. (PubMed, Exp Oncol)
The bioinformatic analysis showed a high CCR7 expression associated with the presence of metastasis (FC = 2.6, p = 0.03) in the Cancer Genome Atlas (TCGA) PCa cohort (PRAD). We showed that CCR7 expression in tumors from young patients is associated with the early onset of the disease and could also be related to lymph node metastasis.
Retrospective data • Journal
|
CCR7 (Chemokine (C-C motif) receptor 7)
|
CCR7 expresion • CCR7 positive
over1year
CC chemokine receptor 7 promotes macrophage recruitment and induces M2-polarization through CC chemokine ligand 19&21 in oral squamous cell carcinoma. (PubMed, Discov Oncol)
CCR7 in OSCC cells promoted recruitment and M2-polarization of THP-1 derived macrophages in vitro by regulating production of CCL19 and CCL21.
Journal
|
CCL19 (C-C Motif Chemokine Ligand 19) • CCR7 (Chemokine (C-C motif) receptor 7)
|
CCR7 expresion • CCR7 positive
almost2years
C-C Chemokine Receptor 7 in Cancer. (PubMed, Cells)
In certain tumors, it may even serve a protective role. Future studies should focus on defining mechanisms that differentially regulate the unfavorable or beneficial role that CCR7 plays in cancer pathophysiology, to be able to improve outcomes in patients who harbor CCR7-positive cancers.
Review • Journal
|
CCR7 (Chemokine (C-C motif) receptor 7)
|
CCR7 positive
over2years
CCR7 in Blood Cancers - Review of Its Pathophysiological Roles and the Potential as a Therapeutic Target. (PubMed, Front Oncol)
Here, we review published data to catalogue CCR7 expression across blood cancers and appraise which classical and novel roles are attributed to this receptor in the pathogenesis of specific hematologic neoplasms. We outline why novel therapeutic strategies targeting CCR7 might provide clinical benefits to patients with CCR7-positive hematopoietic tumors.
Review • Journal
|
CCR7 (Chemokine (C-C motif) receptor 7)
|
CCR7 expresion • CCR7 positive
3years
Inhibition of NADPH oxidase 4 attenuates lymphangiogenesis and tumor metastasis in breast cancer. (PubMed, FASEB J)
Nox4 may increase tumor lymphangiogenesis via ROS/ERK/CCL21 pathway and attract CCR7-positive breast cancer cells to entry lymphatic vessels and distant organs. In conclusion, our results show that Nox4 is a factor that promotes lymphangiogenesis and is a potential target of antitumor metastasis.
Journal
|
CCR7 (Chemokine (C-C motif) receptor 7)
|
ROS1 positive • CCR7 positive